Since the predominant perspectives proposed that the presence of classical ERα and PR was fundamental to endocrine deprivation therapy, previously little evidence linked existing endocrine agents, as well as the hormone signaling transfer system, to the potent research directions and therapeutic target in the triple-negative aggressive subtype of breast cancer, which merited concentration. The gene discussed is PGR; the disease is breast carcinoma.